Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 17/20 | 0.72 |
| ▸ | CLK2 | P49760 | 1/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373450 | 0.90 | CXCR3 (0.75) | CXCR3 | |
| SCHEMBL14373427 | 0.87 | CXCR3 (0.90) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL5465834 | 0.87 | CXCR3 (0.72) | CXCR3MEN1KMT2A | |
| SCHEMBL14373423 | 0.85 | CXCR3 (0.79) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373589 | 0.84 | CLK2 (0.83) | CXCR3CLK2DYRK1ACLK4MEN1 | |
| SCHEMBL14373428 | 0.84 | CXCR3 (1.00) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373595 | 0.83 | CLK2 (0.81) | CXCR3CLK2DYRK1ACLK4MEN1 | |
| SCHEMBL14373593 | 0.82 | CLK2 (0.80) | CXCR3CLK2DYRK1ACLK4MEN1 | |
| SCHEMBL14373584 | 0.82 | CLK2 (1.00) | CXCR3CLK2DYRK1ACLK4MEN1 | |
| SCHEMBL14373437 | 0.82 | CXCR3 (0.83) | CXCR3CLK2DYRK1ACLK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885CLK2 1827/4885DYRK1A 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.